UBS Group set a €125.00 ($148.81) price target on Bayer (FRA:BAYN) in a report published on Thursday, December 7th, www.boersen-zeitung.de reports. The firm currently has a buy rating on the healthcare company’s stock.
BAYN has been the topic of a number of other research reports. S&P Global set a €126.00 ($150.00) price target on Bayer and gave the stock a buy rating in a research report on Thursday, October 26th. Sanford C. Bernstein set a €131.00 ($155.95) price target on Bayer and gave the stock a buy rating in a research report on Wednesday, November 29th. Independent Research set a €120.00 ($142.86) price target on Bayer and gave the stock a neutral rating in a research report on Wednesday, August 23rd. equinet set a €118.00 ($140.48) price objective on Bayer and gave the company a buy rating in a research note on Friday, October 13th. Finally, BNP Paribas set a €130.00 ($154.76) price objective on Bayer and gave the company a buy rating in a research note on Monday, September 25th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of €122.33 ($145.63).
Shares of Bayer (FRA:BAYN) traded down €0.40 ($0.48) during midday trading on Thursday, hitting €104.00 ($123.81). The company had a trading volume of 1,355,645 shares. Bayer has a 52 week low of €97.91 ($116.56) and a 52 week high of €123.82 ($147.40). The company has a market capitalization of $85,780.00 and a PE ratio of 27.88.
ILLEGAL ACTIVITY NOTICE: “Bayer (BAYN) Given a €125.00 Price Target at UBS Group” was first published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://weekherald.com/2017/12/30/ubs-analysts-give-bayer-bayn-a-125-00-price-target.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.